A pre revenue company trading at this MC will surely garner some shorting interest.
i think we need to look at the next cohort as the start of P2, which means cu67 is a P2 asset. The next cohort, which is the first multi dose cohort, is dosing the same schedule as their dose expansion (P2).
unless they change their RP2D. Although renal damage may be a key factor in limiting cumulative dose
A pre revenue company trading at this MC will surely garner some...
-
- There are more pages in this discussion • 301 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.20 |
Change
0.190(2.71%) |
Mkt cap ! $2.305B | |||
| Open | High | Low | Value | Volume |
| $7.12 | $7.34 | $6.95 | $5.698M | 788.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 16776 | $7.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.27 | 197 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |